23 results about "Taurochenodeoxycholic acid" patented technology

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The invention relates to application of taurochenodeoxycholic acid in preparation of a medicine for preventing and treating hypertension. The key effect of the taurochenodeoxycholic acid in prevention and treatment of hypertension is found for the first time, that is, the taurochenodeoxycholic acid can significantly enhance the diastolic function of arteriole of a hypertensive patient, so that the effect of reducing blood pressure is achieved. Therefore, the invention provides a new application of taurochenodeoxycholic acid in preparation of the medicine for preventing and treating hypertension, a new medicine for preventing and treating hypertension is provided clinically, and the taurochenodeoxycholic acid has a good clinical application value and a wide application prospect. The taurochenodeoxycholic acid can be prepared into a medicine, a pharmaceutical composition, food, a health care product or a food additive by utilizing the key effect of the taurochenodeoxycholic acid in hypertension diseases, can be used for treating hypertension diseases including primary hypertension and salt-sensitive hypertension, and has important application value.

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The invention discloses a bile acid derivative and application of the bile acid derivative as an FXR antagonist. The invention discloses a bile acid derivative with a novel structure. The bile acid derivative is a chiral isomer of taurochenodeoxycholic acid (salt). Technicians in the field know that generally, the biological activity of chiral isomers is close, however, the antagonistic activity of the bile acid derivative provided by the invention to farnesoid X receptors is 3-4 times that of the chiral isomers, and the technical effect is unexpected. Therefore, the compound provided by the invention can be used for preparing the farnesoid X receptor antagonist, and has the application prospect of being developed into drugs for preventing, treating or relieving diseases by antagonizing the farnesoid X receptor.

The invention provides a lipid nanoparticle based on taurochenodeoxycholic acid modification as well as a preparation method and application thereof. The lipid nanoparticle comprises nucleic acid and a lipid carrier encapsulating the nucleic acid, the lipid carrier is prepared from the following components in percentage by mole: 40 to 65 percent of ionized lipid, 5 to 20 percent of structural phospholipid, 20 to 50 percent of sterol component and 0.5 to 5 percent of PEG (Polyethylene Glycol)-lipid, wherein the sterol component comprises cholesterol and taurochenodeoxycholic acid. By replacing cholesterol with taurochenodeoxycholic acid, the membrane order degree and fluidity of the lipid carrier are effectively adjusted, and the targeted delivery and endosome release efficiency of LNP to liver cells is remarkably improved, so that an LNP delivery system can obtain a more remarkable and lasting Lp (a) reduction effect under the same or lower dosage; by optimizing the LNP formula, it is ensured that the LNP preparation has higher controllability and reliability in the production and storage process.

The invention provides two new applications of taurochenodeoxycholic acid (TCDCA) in the field of alcohol related liver diseases (ALD), and belongs to the field of biological medicines. First, the invention proposes that TCDCA is used as a biomarker for auxiliary diagnosis and / or staging evaluation of ALD for the first time. Clinical research finds that the level of TCDCA in human serum is in significant positive correlation with the severity of ALD, and the TCDCA has extremely high accuracy in ALD diagnosis and can effectively assist in distinguishing different stages of diseases. Secondly, the invention discloses an application of TCDCA in preparation of a medicine for preventing and / or treating ALD (Atomic Lymphosis Disease). Researches show that the TCDCA can save ethanol-induced liver cell activity decline in a concentration-dependent manner and improve liver pathological indexes of mice. The TCDCA has double values of being used as an excellent biomarker and an effective prevention and treatment component, and a brand new strategy is provided for accurate diagnosis and prevention and treatment of ALD.

The invention discloses human body simulation fasting gastric juice and a preparation method thereof, and belongs to the technical field of in-vitro dissolution experiments of pharmaceutical preparations. The invention aims to solve the problems that in the prior art, simulated gastric juice has significant differences with real empty gastric juice of a human body in the aspects of surface tension, osmotic pressure and buffer capacity, so that an in-vitro evaluation result of a dissolution behavior of a pharmaceutical preparation is inaccurate, and scientificity and reliability of an in-vitro dissolution experiment of a drug are influenced. The human body simulated fasting gastric juice comprises the following components: 2 to 30 mg / mL of bovine serum albumin, 0 to 7.517 E-05 mol / L of glycocholic acid or glycocholate, 0 to 7.421 E-05 mol / L of glycochenodeoxycholic acid or glycochenodeoxycholate, 0 to 8.369 E-04 mol / L of taurocholic acid or taurocholate, 0 to 9.005 E-04 mol / L of taurochenodeoxycholic acid or taurochenodeoxycholate, 0.025 to 0.138 g / L of calcium chloride, 0.478 to 1.12 g / L of potassium chloride, 0.015 to 0.063 g / L of magnesium chloride, 2.05 to 5.26 g / L of sodium chloride, 0.037 to 0.411 g / L of sodium dihydrogen phosphate and a pH regulator. The method can be used for evaluating the dissolution behavior of the pharmaceutical preparation in vitro, and is suitable for the fields of drug development, quality control and the like.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The invention provides a chicken bile extract taurochenodeoxycholic acid as well as an extraction and separation process and application thereof, solves the technical problems of interference of chicken gallbladder protein and fat and poor water solubility of TCDCA, greatly improves the separation purity, is suitable for industrial production, and has a wide application prospect. The taurochenodeoxycholic acid with relatively high purity is separated from the taurochenodeoxycholic acid and is used for reducing and lowering the stress degree of the ducks.

Disclosed in the present invention are a kit for detecting 15 bile acid profiles and three bile acid precursors in serum simultaneously and a detection method therefor. The 15 bile acid profiles comprise: cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid, glycocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, glycolithocholic acid, taurocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid and taurolithocholic acid; and the three bile acid precursors comprise: 3α,7α-dihydroxycoprostanic acid, 3α,7α,12α-trihydroxycholestanoic acid and 7α-hydroxy-4-cholesten-3-one. The kit and detection method of the present invention enable the simultaneous and accurate detection of the 15 bile acid profiles and the three bile acid precursors, with a short detection time and a high detection accuracy. This, to a certain extent, meets the clinical need for assessing the enterohepatic cycle composed of the biliary system, intestines, portal venous circulation and hepatocytes.

The invention provides a method and a kit for diagnosing or identifying whether an individual suffers from liver cancer or not by detecting a metabolic biomarker, and the metabolic biomarker comprises 1-stearoyl-2-arachidonyl-sn-glycerol, NG, S-glycerol, S-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol and N-glycerol. The compound is selected from one or more of N, N-dimethyl-L-arginine, N, N-dimethyl-L-arginine (ADMA), taurochenodeoxycholic acid, proline-valine (Pro-Val) and 1-oleoyl-L-alpha-lysophosphatidic acid.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and polyinosinic acid combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment by regulating and controlling the antigen presentation function of cDC1, and the treatment effect of polyinosinic-cytidylic acid is improved. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and polyinosinic-cytidylic acid can better inhibit tumor growth, can effectively promote CD8 + T cell infiltration in tumors, has more cDC1 infiltration in tumor tissues, shows a stronger inhibition effect on tumors, and can be used for preparing drugs for treating tumors. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, alpha-type enzyme, lactic dehydrogenase, beta-type enzyme and glucose dehydrogenase are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multipath enzymatic reaction, and the method has a relatively high application value.

The invention discloses a 7alpha-hydroxysteroid dehydrogenase mutant, the amino acid sequence of which is an amino acid sequence obtained by mutating 94th amino acid, 259th amino acid or 199th amino acid of SEQ ID NO: 1, or an amino acid sequence obtained by truncating 8 or 9 amino acid residues at the C-terminal of SEQ ID NO: 1, or the 94th amino acid mutation is an amino acid sequence of simultaneously truncating one or two amino acid residues at the C-terminal; wherein the SEQ ID NO: 1 is an amino acid sequence of the 7 alpha-hydroxysteroid dehydrogenase. According to the mutant, the specific recognition capacity of 7alpha-HSDH on taurochenodeoxycholic acid (TCCA) is remarkably enhanced, non-specific catalysis of the 7alpha-HSDH on taurochenodeoxycholic acid (TCCA) is inhibited, and generation of by-products TUCA and 3, 12-HOCT is remarkably reduced.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, the alpha-type enzyme, the lactic dehydrogenase and the beta-type enzyme are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multi-path enzymatic reaction, and the method has a relatively high application value.

The invention belongs to the technical field of biology, and particularly relates to an NAD (H) dependent type 3 alpha-hydroxysteroid dehydrogenase mutant E139T, the amino acid sequence of the mutant E139T is shown as SEQ ID NO: 1, and the mutant E139T is obtained by changing the 139th amino acid of wild type 3 alpha-hydroxysteroid dehydrogenase of which the amino acid sequence is SEQ ID NO: 2 into Thr from Glu. The DNA coding sequence of the gene is as shown in SEQ ID NO: 3. The mutant E139T can catalyze oxidation of alpha hydroxyl at C3 site of taurochenodeoxycholic acid (TCDCA) and tauroursodeoxycholic acid (TUDCA), and the activity of the mutant E139T is 1.12 times and 1.38 times that of wild type 3 alpha-hydroxysteroid dehydrogenase. The application prospect in clinical examination of the total bile acid content is huge.

The invention discloses an application of taurochenodeoxycholic acid in preparation of a medicine for recovering functions of damaged hematopoietic cells, taurochenodeoxycholic acid and TCDCA are combined bile acids, the combined bile acids are formed by combining chenodeoxycholic acid Chenodeoxycholic acid, CDCA and taurine, and the combined bile acids belong to secondary bile acids. The compound naturally exists in bile of mammals, has various biological functions, and particularly plays an important role in metabolism regulation, anti-inflammation, immunoregulation and the like. The TCDCA is found to be capable of recovering the number and functions of hematopoietic cells of mice with hematopoietic damage caused by long-term drinking of low-temperature water besides the functions.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and PD-1 antibody combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment and improve the treatment effect of the PD-1 antibody by regulating and controlling the function of cDC1. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and the PD-1 antibody can better inhibit tumor growth, and can effectively promote CD8 + T cell infiltration in tumor, so that more cDC1 infiltration exists in tumor tissue, the stronger inhibition effect on tumor is displayed, and the application of chenodeoxycholic acid and PD-1 antibody in tumor treatment is realized. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention relates to the technical field of medicines, and discloses application of chicken gall powder in burn treatment. Experimental results show that the chicken gall powder is remarkable in burn treatment effect and can be used as a substitute medicine for treating burns with the bear gall powder, the total cholic acid content of the bear gall powder and the total cholic acid content of the chicken gall powder are similar, the bear gall powder and the chicken gall powder both contain tauroursodedeoxycholic acid, taurochenodeoxycholic acid and other active ingredients, amino acids and microelements contained in the bear gall powder are highly consistent in composition, and the chicken gall powder has a good treatment effect on burns. The homology of the components lays a material foundation for the pharmacodynamic equivalence of the chicken gall powder, the chicken gall powder is low in price, and the raw materials are easy to obtain.

The invention belongs to the technical field of biology, and particularly relates to an NAD (H) dependent type 3 alpha-hydroxysteroid dehydrogenase mutant E139S, the amino acid sequence of the mutant E139S is shown as SEQ ID NO: 1, and the mutant E139S is obtained by changing the 139th amino acid of wild type 3 alpha-hydroxysteroid dehydrogenase of which the amino acid sequence is SEQ ID NO: 2 into Ser from Glu. The DNA coding sequence of the gene is as shown in SEQ ID NO: 3. The mutant E139S can catalyze oxidation of alpha hydroxyl at C3 site of taurochenodeoxycholic acid (TCDCA) and tauroursodeoxycholic acid (TUDCA), and the activity of the mutant E139S is 1.26 times and 1.73 times that of wild type 3 alpha-hydroxysteroid dehydrogenase. The application prospect in clinical examination of the total bile acid content is huge.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid by using three enzymes, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, the immobilized enzymes of the alpha-type enzyme, the lactic dehydrogenase and the beta-type enzyme are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multi-path enzymatic reaction, and the method has a relatively high application value.

This invention relates to the field of natural product raw material preparation technology, specifically to a method for preparing high-quality chicken bile extract. In this technical solution, chicken bile is concentrated to obtain a first concentrated material. This first concentrated material is then extracted with diethyl ether, and the aqueous phase is separated. The aqueous phase is concentrated to obtain a second concentrated material, which is mixed with anhydrous ethanol, allowed to stand, and then filtered to obtain the supernatant. The supernatant is then concentrated to obtain chicken bile extract. The chicken bile extract prepared by this method can have a taurine chenodeoxycholic acid content of up to 50% or more. This solution can solve the technical problems of high impurity content and unsatisfactory taurine chenodeoxycholic acid content in existing chicken bile extracts. This technical solution, through ether extraction and ethanol precipitation, increases the content of the active ingredient in chicken bile extract, thereby improving the quality of the chicken bile extract, reducing subsequent processing steps, and meeting market demand for high-quality chicken bile extract, thus having ideal application and promotion prospects.

The invention provides a DC vaccine for treating melanoma and a preparation method and application thereof, and belongs to the field of biological medicine. It is found for the first time that the treatment effect of cDC1 cells treated by taurochenodeoxycholic acid on melanoma is remarkably enhanced, a cDC1 vaccine treated by taurochenodeoxycholic acid has a stronger CD8 + T cell activation effect, anti-tumor immune response can be started more quickly, a stronger tumor killing effect is generated, and a method for treating melanoma is provided for clinic.